# Tarveda Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tarveda-therapeutics

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.tarveda.com
- Total disclosed funding: $113M
- Latest round: Series D (Jan 31, 2017)
- Investors on record: 6

## About

Tarveda Therapeutics, Inc. focuses on developing innovative therapeutics utilizing its proprietary drug delivery platform to enhance cancer treatment outcomes. The company aims to improve patient care through targeted therapies.Founded in 2011 and headquartered in Watertown, US, Tarveda Therapeutics, Inc. is dedicated to developing nanotechnology-based therapeutics for cancer treatment. The company raised USD 30 mn in Series D funding on January 31, 2017, led by Versant Ventures with additional investment from Flagship Pioneering, +ND Capital, New Enterprise Associates, and Novo Holdings. The total funds raised by the company amount to USD 30 mn, achieving a current valuation of USD 93.694 mn. The founder, Omid Farokhzad, is recognized for his expertise in the pharmaceutical field.Tarveda Therapeutics specializes in developing innovative drug delivery systems aimed at targeting cancer cells effectively. Their proprietary technology enables the creation of advanced therapeutics designed to improve the efficacy and safety of existing cancer treatments, addressing critical needs within oncology.The company's revenue is primarily generated through the commercialization of its proprietary cancer therapeutics and drug delivery systems. Revenue structures are based on strategic partnerships and collaborations that facilitate access to advanced oncology treatments, with a focus on achieving sustainable growth in the competitive biopharmaceutical market.Tarveda Therapeutics plans to leverage the USD 30 mn raised in their recent Series D financing to expand their product pipeline and accelerate the development of their therapeutics. The company is also exploring entry into new global markets, focusing on Europe and Asia by 2025. Their strategy includes launching additional drug candidates that will enhance treatment options for cancer patients, further solidifying their presence in oncology.

## Funding rounds

- Series D, Jan 31, 2017, $30M — Flagship Pioneering, New Enterprise Associates, Versant Ventures, +ND Capital, Novo Holdings
- Series C, Jan 30, 2017, $13M — Flagship Pioneering, New Enterprise Associates, Novo Holdings, TaiAn Technologies Corporation, +ND Capital
- Series C, Jan 15, 2016, $26M — Flagship Pioneering, New Enterprise Associates, TaiAn Technologies Corporation, +ND Capital, Novo Holdings
- Series B, Jan 7, 2015, $21M — Flagship Pioneering, New Enterprise Associates, TaiAn Technologies Corporation, +ND Capital
- Series B, Mar 11, 2014, $0.5M — New Enterprise Associates, +ND Capital
- Series B, Dec 23, 2013, $5M — Flagship Pioneering, +ND Capital
- Series B, Dec 12, 2012, $16M — Flagship Pioneering, New Enterprise Associates, +ND Capital
- Series A, Sep 2, 2011, $2.8M — Flagship Pioneering, New Enterprise Associates, +ND Capital

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B, Series C, Series D
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B, Series C, Series D
- +ND Capital (https://capitalatlas.ai/funds/nd-capital) — Series A, Series B, Series C, Series D
- TaiAn Technologies Corporation (https://capitalatlas.ai/funds/taian-technologies-corporation) — Series B, Series C
- Novo Holdings — Series C, Series D
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series D